ACCESS Newswire·Nov 10, 2026, 4:05 PM ET

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026

Dermata Therapeutics generated its first product revenue following the August 25, 2026, launch of Tome Foundational Treatment via its direct-to-consumer ecommerce platform.
The company transitioned from a development-stage pharmaceutical entity to a revenue-generating commercial skincare business with approximately 30% of initial orders coming from subscriptions.
Positive clinical study results from October 2026 showed improvements in skin appearance for over 71% of participants after a single treatment, supporting the brand's "Studied Skincare" positioning.
A clinical trial for the second planned product, Tome Clearing Treatment for acne, began enrollment in October 2026 with a target launch in the first half of 2027.
Net sales for the quarter ended September 30, 2026, were $74,000, resulting in a gross profit of $40,000 with an approximate 54% profit margin.
Cash, cash equivalents, restricted cash decreased to $5.0 million as of September 30, 2026, from $7.5 million at year-end 2025, with operations sufficient to fund activities into the first quarter of 2027.
Selling, general administrative expenses increased to $2.8 million for the quarter due to commercialization activities, compensation reallocation, litigation, new trademarks.
Research development expenses decreased to $0.1 million for the quarter as employee duties shifted to support the commercial launch of Tome Foundational Treatment.